Moderna to receive the EUA this Thursday

December 16, 2020
Moderna to receive the EUA this Thursday

Its proven efficacy made Moderna’s COVID-19 vaccine to be a few steps away from receiving the EUA

Moderna is just a few steps away from receiving the US Food and Drug Administration’s emergency use authorization (EUA).

According to insiders, Moderna’s experimental COVID-19 vaccine meets the requirements, as it is “highly effective” in preventing the potentially deadly complications caused by the COVID-19 infection. Moreover, the Administration’s review confirms that the potential medicine is indeed 94.1% effective.

“The 2-dose vaccination regimen was highly effective in preventing PCR-confirmed COVID-19 occurring at least 14 days after receipt of the second dose,” read the FDA’s statement. An official decision will be made on Thursday and could be available to the public as early as next week.

Following the news, Moderna stock price traded 1.24% higher.

Sources: cnbc.com, thestreet.com

This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.


You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.



This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.

Recently Added